Effect of the antioxidants on Vinblastin and Vincristine treated Human erythrocytes in-vitro

Paper Details

Research Paper 01/12/2019
Views (319) Download (16)

Effect of the antioxidants on Vinblastin and Vincristine treated Human erythrocytes in-vitro

Uzma Faridi
Int. J. Biosci.15( 6), 82-88, December 2019.
Certificate: IJB 2019 [Generate Certificate]


Vinca alkaloids are one of the earliest microtubule-targeting plant based anticancer drugs approved clinically.  The Food and Drug Administration (FDA) approved vinblastin and vincristine are used for the of different tumor types like leukemia, Hodgkin’s lymphoma, lung cancer, breast cancer in 1961 and 1963, respectively. Although these drugs are commonly used as anticancer drug but still constitute a substantial drawbacks. The side-effects of vinca alkaloids consist of toxicity to blood cells, nausea, vomiting, and many more. In present the haemolytic effect of vinblastin and vincristine was investigated on normal erythrocytes and the protective effect of ascorbic acid, β Carotene, quercetin and tocopherol in presence of these drugs. To study the effect of selected antioxidants and vinca alkaloids osmotic fragility assay was performed. The results suggest that β Caroteneexhibits a protective effect against vinblastin-induced haematological toxicity.


Anitha Sri S. Pharmacological activity of Vinca alkaloids. Journal of pharmacognosyand phytochemistry4, 27-34.

Barr RD, Davidson AR, Jung LK, Pai KM. Erythrocytotoxicity Induced by Cancer Chemotherapeutic Agents: In Vitro Studies of Osmotic Fragility and Methaemoglobin Generation. Scandinavian journal of haematology 25(4), 363-368.

Birben E, Sahiner UM, Sackesen C. 2012. Oxidative stress and antioxidant defense. World Allergy Organ Journal 5(1), 1. http://dx.doi.org/10.1097/WOX.0b013e3182439613

Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O’Brien M, Van Belle S, Vaupel P. 2005. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68(1), 12-21. http://dx.doi.org/10.1159/000083129

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre, LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians 68(6), 394-424. http://dx.doi.org/10.3322/caac.21492

Budman DR. Vinorelbine (Navelbiner): A Third-Generation Vinca Alkaloid Cancer investigation 15(5), 475-490. http://dx.doi.org/10.3109/07357909709047587

De Conti RC, Muggia F, Cummings FJ. Clinical and pharmacological studies with D-tetrandrine In: Proceedings of the American Association for Cancer Research and ASCO, San Diego, California 16, 96.

Doucet Jay Zu-hua Gao, Leslie Mac Laren A, Vivian McAlister C. 2004. Modification of xenoantigens on porcine erythrocytes for xenotransfusion. Surgery 135(2). http://dx.doi.org/10.1016/j.surg.2003.08.013

Erhola M, Toyokuni S, Okada K. Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8-hydroxy-20-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Letter 409(2), 287–291.

Herman EH, Chadwick DP, Mhatre RM. 1974. Comparison of the acute hemolytic and cardiovascular actions of Ellipticine and some Ellipticineanalogs. Cancer Chemotherapy Reports. 58, 637–643.

Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. 1976. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules.In-vitro Cancer Research 36(10), 3798-3802.

Hristozov D, Gadjeva V, Vlaykova T. 2001. Evaluation of oxidative stress in patients with cancer. Archives of Physiology and Biochemistry 109(4), 331–336. http://dx.doi.org/1076/apab.109.4.331.4248

Jacobs MH. Osmotic properties of the erythrocyte III The applicability of osmotic laws to the rate of hemolysis in hypotonic solutions of non-electrolytes. Biological Bulletin 62(2), 178–194.

Jiahui Liu, Zhichong Wang. 2015. Increased Oxidative Stress as a Selective Anticancer Therapy. Oxidative Medicine and Cellular Longevity. http://dx.doi.org/10.1155/2015/294303

Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer research51(8), 2212-2222. http://dx.doi.org/10.1016/j.bmcl.2018.06.044

Kwame Asare. Anemia of Critical Illness. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28(10), 1267–1282. http://dx.doi.org/10.1592/phco.28.10.1267

Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF. 6th ed. Hamilton (ON): BC Decker Incorporation;. Holland-Freide cancer medicine.

Lee IP, Dixon RL. 1972. A possible mechanism for Ellipticine induced hemolysis of human red blood cells. Federation proceedings 31, 554.

Li, YQ, Hu R, Zhong LH. 2016. Synergistic effect of trehalose and saccharosepretreatment on maintenance of lyophilized human red blood cell quality. Tropical Journal of Pharmaceutical Research. 15(3), 527–533.

Lubran MM. Hematologic side effects of drugs. The Annals of Clinical& Laboratory Science. 19(2), 114–121.

Miki M, Tamai H, Mino M. Free-radical chain oxidation of rat red blood cells by molecular oxygen its inhibition by -tocopherol. Archivesof Biochemistry and Biophysics 258(2), 373–380. http://dx.doi.org/10.1016/0003-9861(87)90358-4

Moudi M, Go R, Yien CYS, Nazre M. 2013. Vinca alkaloids. International journal of preventive medicine 4(11), 1231.

Matés JM, Pérez-Góme C, De Castro IN. 1999. Antioxidant enzymes and human diseases. Clinical biochemistry 32(8), p595-603. http://dx.doi.org/10.1016/s0009-9120(99)00075-2

Niki E, Komuro E, Takahashi M, Urano S, Ito E, Terao K. Oxidative hemolysis of erythrocytes and its inhibition by free radical scavengers. Journal of Biological Chemistry 263(36), 19809-19814.

Petz LD, Garratty G. 1975. Drug-induced haemolytic anemia. Clinics in haematology 4(1), 181-197.

Quirt I, Robeson C, Lau CY. Canadian Eprex Oncology Study Group Epoetinalfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. Journal of Clinical Oncology 19(21), 4126–4134.

Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert opinion on drug safety 10(3), 449-462. http://dx.doi.org/10.1517/14740338.2011.563235

Salama A. 2009. Drug-induced immune hemolytic anemia. Expert opinion on drug safety 8(1), 73-79. http://dx.doi.org/10.1517/14740330802577351

Vincent PC. 1986. Drug-induced aplastic anaemia and agranulocytosis. Drugs 1, 52–63, http://dx.doi.org/10.2165/0000349519863101000004